Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of VX-150 in healthy adults
NL-OMON41908Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing VX-150 with Placebo (2 arms). Primary endpoints: Safety and tolerability of single doses of VX-150 and Safety and tolerability of multiple doses of VX-150. Started Jan 2015; status: active, not recruiting.
02
Drugs
VX-150
03
Conditions
pain
Beyond the preview
Go deeper on NL-OMON41908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41908.